Specialist API CDMO acquired by GHO Capital

16 Mar 2019

Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.

GHO Capital has acquired a majority stake in Sterling Pharma Solutions, a specialist in complex and difficult to manufacture APIs.

Specialist API CDMO acquired by GHO Capital

Headquartered in Newcastle upon Tyne, UK, Sterling is a leading provider of API development and manufacturing, with a reputation for world class quality standards. This is reflected in Sterling’s long-term relationships with blue-chip pharmaceutical and animal health clients, as well as a strong track record with global regulators including the FDA and EMA.

Sterling delivers a full-service offering of API development and GMP manufacturing to support its customers throughout the entire product lifecycle. The company is a provider of specialist services from clinical development through market launch to commercial supply.

Outsourced small molecule API development and manufacturing is growing steadily at approximately 7% per annum. This is overlaid with a long-term trend towards increasing molecule complexity, driving higher market growth rates in complex chemistry, where Sterling is an industry leader in Europe.

GHO Capital brings extensive sectoral expertise and networks in the global pharmaceutical and animal health industries, to support management in accelerating Sterling’s international growth.

Kevin Cook, CEO of Sterling Pharma Solutions, commented: “We are delighted to partner with GHO Capital, whose expertise in the pharmaceuticals space and track record of supporting companies expand internationally will be invaluable in facilitating the next stage of our growth in Europe and in the US.”

Alan MacKay, Partner at GHO Capital, commented: “Sterling provides a compelling opportunity to partner with a best in class management team to support the global demand for complex chemistry in pharmaceuticals.”

“Sterling is today a leader in Europe from its UK operations and the plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.

Read More

Related news

Global collaboration to innovate more natural and additive-free nutraceuticals

Global collaboration to innovate more natural and additive-free nutraceuticals

11 Apr 2019

Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
New China-based biotechs fueling growth in manufacturing across China

New China-based biotechs fueling growth in manufacturing across China

9 Apr 2019

New guidelines will see poorer quality manufacturers drop out of the market.

Read more 
TTP spin-out to commercialise next-generation cell-sorting technology

TTP spin-out to commercialise next-generation cell-sorting technology

7 Apr 2019

Highway 1 addresses a major unmet need for improved cell-sorting technology, with applications including development of cell therapies, liquid biopsy diagnostics, and high-throughput drug discovery.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more 
'Drugs from bugs' joint venture

'Drugs from bugs' joint venture

4 Apr 2019

Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.

Read more 
BASF launches three new active ingredients derived from the rambutan tree

BASF launches three new active ingredients derived from the rambutan tree

2 Apr 2019

The ingredients are extracted from the first organically certified rambutan gardens in Vietnam.

Read more 
Sartorius integrates online biomass measurement to its ambr systems for microbial applications

Sartorius integrates online biomass measurement to its ambr systems for microbial applications

1 Apr 2019

Scientists to rapidly obtain detailed process understanding and control over their microbial cultures.

Read more 
Cambrex doubles cGMP liquid filling capacity at its Mirabel facility

Cambrex doubles cGMP liquid filling capacity at its Mirabel facility

1 Apr 2019

Investment will improve production cycle time and provide greater flexibility to customers.

Read more